133 related articles for article (PubMed ID: 37134151)
1. Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer.
Wang M; Wisniewski CA; Xiong C; Chhoy P; Goel HL; Kumar A; Zhu LJ; Li R; St Louis PA; Ferreira LM; Pakula H; Xu Z; Loda M; Jiang Z; Brehm MA; Mercurio AM
Sci Transl Med; 2023 May; 15(694):eade5855. PubMed ID: 37134151
[TBL] [Abstract][Full Text] [Related]
2. VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.
Goel HL; Chang C; Pursell B; Leav I; Lyle S; Xi HS; Hsieh CC; Adisetiyo H; Roy-Burman P; Coleman IM; Nelson PS; Vessella RL; Davis RJ; Plymate SR; Mercurio AM
Cancer Discov; 2012 Oct; 2(10):906-21. PubMed ID: 22777769
[TBL] [Abstract][Full Text] [Related]
3. Association of plasma NRP2 and VEGF-C levels with prostate cancer disease severity.
Mullen SA; Das D; Ziamiavaghi N; High R; Datta K; Teply BA
Prostate; 2024 Feb; 84(3):277-284. PubMed ID: 37942701
[TBL] [Abstract][Full Text] [Related]
4. Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate.
Borkowetz A; Froehner M; Rauner M; Conrad S; Erdmann K; Mayr T; Datta K; Hofbauer LC; Baretton GB; Wirth M; Fuessel S; Toma M; Muders MH
Int J Cancer; 2020 May; 146(9):2619-2627. PubMed ID: 31509606
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.
Gray MJ; Van Buren G; Dallas NA; Xia L; Wang X; Yang AD; Somcio RJ; Lin YG; Lim S; Fan F; Mangala LS; Arumugam T; Logsdon CD; Lopez-Berestein G; Sood AK; Ellis LM
J Natl Cancer Inst; 2008 Jan; 100(2):109-20. PubMed ID: 18182619
[TBL] [Abstract][Full Text] [Related]
6. A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression.
Geretti E; van Meeteren LA; Shimizu A; Dudley AC; Claesson-Welsh L; Klagsbrun M
Mol Cancer Res; 2010 Aug; 8(8):1063-73. PubMed ID: 20651020
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer.
Xu Z; Goel HL; Burkart C; Burman L; Chong YE; Barber AG; Geng Y; Zhai L; Wang M; Kumar A; Menefee A; Polizzi C; Eide L; Rauch K; Rahman J; Hamel K; Fogassy Z; Klopp-Savino S; Paz S; Zhang M; Cubitt A; Nangle LA; Mercurio AM
Sci Transl Med; 2023 May; 15(694):eadf1128. PubMed ID: 37134152
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2.
Coma S; Shimizu A; Klagsbrun M
Cell Adh Migr; 2011; 5(3):266-75. PubMed ID: 21610314
[TBL] [Abstract][Full Text] [Related]
9. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
[TBL] [Abstract][Full Text] [Related]
10. 131I-labeled monoclonal antibody targeting neuropilin receptor type-2 for tumor SPECT imaging.
Chen L; Wang L; Yan J; Ma C; Lu J; Chen G; Chen S; Su F; Wang W; Su X
Int J Oncol; 2017 Feb; 50(2):649-659. PubMed ID: 28000859
[TBL] [Abstract][Full Text] [Related]
11. Neuropilin-2 promotes branching morphogenesis in the mouse mammary gland.
Goel HL; Bae D; Pursell B; Gouvin LM; Lu S; Mercurio AM
Development; 2011 Jul; 138(14):2969-76. PubMed ID: 21693513
[TBL] [Abstract][Full Text] [Related]
12. Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.
Wang J; Li J; Yin L; Pu T; Wei J; Karthikeyan V; Lin TP; Gao AC; Wu BJ
Oncogene; 2022 Sep; 41(37):4307-4317. PubMed ID: 35986103
[TBL] [Abstract][Full Text] [Related]
13. ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer.
Wang Z; Zhang X; Li W; Su Q; Huang Z; Zhang X; Chen H; Mo C; Huang B; Ou W; Chen J; Zhao G; Chen L; Shao L
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301812
[TBL] [Abstract][Full Text] [Related]
14. Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma.
Kawakami T; Tokunaga T; Hatanaka H; Kijima H; Yamazaki H; Abe Y; Osamura Y; Inoue H; Ueyama Y; Nakamura M
Cancer; 2002 Nov; 95(10):2196-201. PubMed ID: 12412174
[TBL] [Abstract][Full Text] [Related]
15. Neuropilin-2 mediates lymphangiogenesis of colorectal carcinoma via a VEGFC/VEGFR3 independent signaling.
Ou JJ; Wei X; Peng Y; Zha L; Zhou RB; Shi H; Zhou Q; Liang HJ
Cancer Lett; 2015 Mar; 358(2):200-209. PubMed ID: 25543087
[TBL] [Abstract][Full Text] [Related]
16. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
17. Neuropilin-2 expression in papillary thyroid carcinoma: correlation with VEGF-D expression, lymph node metastasis, and VEGF-D-induced aggressive cancer cell phenotype.
Yasuoka H; Kodama R; Hirokawa M; Takamura Y; Miyauchi A; Inagaki M; Sanke T; Nakamura Y
J Clin Endocrinol Metab; 2011 Nov; 96(11):E1857-61. PubMed ID: 21880798
[TBL] [Abstract][Full Text] [Related]
18. CPSF4 promotes tumor-initiating phenotype by enhancing VEGF/NRP2/TAZ signaling in lung cancer.
Song Y; Sun K; Gong L; Shi L; Qin T; Wang S; Deng W; Chen W; Zheng F; Li G
Med Oncol; 2022 Dec; 40(1):62. PubMed ID: 36567417
[TBL] [Abstract][Full Text] [Related]
19. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer.
Xu Y; Song G; Xie S; Jiang W; Chen X; Chu M; Hu X; Wang ZW
Mol Ther; 2021 Jun; 29(6):1958-1969. PubMed ID: 33932597
[TBL] [Abstract][Full Text] [Related]
20. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
[Next] [New Search]
